0|10000|Public
40|$|Vinylogous ureas 2 -amino- 5, 6, 7, 8 -tetrahydro- 4 H-cyclohepta[b]thiophene- 3 -carboxamide and N-[3 -(aminocarbonyl) - 4, 5 -dimethyl- 2 -thienyl]- 2 -furancarboxamide (compounds 1 and 2, respectively) were {{recently}} identified to be modestly potent inhibitors of the RNase H activity of HIV- 1 and HIV- 2 <b>reverse</b> <b>transcriptase</b> (RT). Both compounds shared a 3 -CONH 2 -substituted thiophene ring but were otherwise structurally unrelated, which prevented a precise {{definition of the}} pharmacophore. We have therefore examined a larger series of vinylogous ureas carrying amide, amine, and cycloalkane modifications of the thiophene ring of compound 1. While cycloheptane- and cyclohexane-substituted derivatives retained potency, cyclopentane and cyclooctane substitutions eliminated activity. In {{the presence of a}} cycloheptane ring, modifying the 2 -NH 2 or 3 -CONH 2 functions decreased the potency. With respect to compound 2, vinylogous ureas whose dimethylthiophene ring contained modifications of the 2 -NH 2 and 3 -CONH 2 functions were investigated. 2 -NH 2 -modified analogs displayed potency equivalent to or enhanced over that of compound 2, the most active of which, compound 16, reflected intramolecular cyclization of the 2 -NH 2 and 3 -CONH 2 groups. Molecular modeling was used to define an inhibitor binding site in the p 51 thumb subdomain, suggesting that an interaction with the catalytically conserved His 539 of the p 66 RNase H domain could underlie inhibition of RNase H activity. Collectively, our data indicate that multiple functional groups of vinylogous ureas contribute to their potencies as RNase H inhibitors. Finally, single-molecule spectroscopy indicates that vinylogous ureas have the property of <b>altering</b> the <b>reverse</b> <b>transcriptase</b> orientation on a model RNA-DNA hybrid mimicking initiation plus-strand DNA synthesis...|$|R
40|$|The {{efficiency}} of three commonly used <b>reverse</b> <b>transcriptases,</b> namely Moloney Murine Leukaemia Virus (M-MuLV) <b>reverse</b> <b>transcriptase,</b> RNase H [...] M-MuLV <b>reverse</b> <b>transcriptase</b> and Avian Myeloblastoma Leukaemia Virus (AMV) <b>reverse</b> <b>transcriptase</b> (RT), have been compared in RT-PCR amplification of antibody genes. These enzymes differed significantly in their {{efficiency of}} cDNA synthesis {{as indicated by}} the degree of V gene amplification by PCR; Moloney Murine Leukaemia Virus (M-MuLV) <b>reverse</b> <b>transcriptase</b> and RNase H [...] M-MuLV <b>reverse</b> <b>transcriptase</b> produced greater amplification of the human V-gene repertoire using RT-PCR than that of the Avian Myeloblastoma Leukaemia Virus (AMV) <b>reverse</b> <b>transcriptase...</b>|$|R
50|$|Efavirenz is a non-nucleoside <b>reverse</b> <b>transcriptase</b> {{inhibitor}} (NNRTI) of HIV-1. Emtricitabine is a nucleoside <b>reverse</b> <b>transcriptase</b> inhibitor (NRTI) of HIV-1.Tenofovir is a nucleotide <b>reverse</b> <b>transcriptase</b> inhibitor of HIV-1, {{and it can}} {{be classified}} as an NtRTI. These three drugs work in combination to target the HIV <b>reverse</b> <b>transcriptase</b> protein in three ways, which reduces the virus’s capacity to mutate.|$|R
40|$|<b>Reverse</b> <b>transcriptases</b> {{from human}} {{immunodeficiency}} virus type 1 (HIV- 1), HIV- 2, and simian immunodeficiency virus (SIV) were investigated with respect to susceptibilities to the <b>reverse</b> <b>transcriptase</b> inhibitors foscarnet and 3 '-azido- 3 '-deoxythymidine triphosphate (AZTTP). The different <b>reverse</b> <b>transcriptases</b> had the same sensitivity to foscarnet (50 % inhibition at 0. 10 to 0. 16 microM). The Ki values for AZTTP were 0. 01 to 0. 02 microM for HIV- 1 <b>reverse</b> <b>transcriptase</b> and 0. 02 to 0. 03 microM for HIV- 2 and SIVMAC <b>reverse</b> <b>transcriptases...</b>|$|R
40|$|The {{hepadnavirus}} <b>reverse</b> <b>transcriptase</b> binds cotranslationally to the viral pregenomic RNA. This ribonucleoprotein {{complex is}} then encapsidated into nascent viral core particles, where the <b>reverse</b> <b>transcriptase</b> copies the viral RNA into DNA. Here {{we report that}} 75 % of the duck hepatitis B virus <b>reverse</b> <b>transcriptase</b> present in transfected LMH cells does not follow this well-known pathway but rather exists in the cell separate from the core protein or nucleocapsids. The nonencapsidated <b>reverse</b> <b>transcriptase</b> is also abundant in infected duck liver. The nonencapsidated <b>reverse</b> <b>transcriptase</b> exists as {{a complex set of}} isoforms that are most likely produced by posttranslational modification. Interestingly, only the smallest of these isoforms is encapsidated into viral core particles. The nonencapsidated <b>reverse</b> <b>transcriptase</b> is bound to a large cellular cytoplasmic structure(s) in a detergent-sensitive complex. The cellular distribution of the <b>reverse</b> <b>transcriptase</b> only partially overlaps that of the core protein, and this distribution is unaffected by blocking encapsidation. These observations raise the possibilities that the metabolic fate of the <b>reverse</b> <b>transcriptase</b> may be posttranscriptionally regulated and that the <b>reverse</b> <b>transcriptase</b> may have roles in the viral replication cycle beyond its well-known function in copying the viral genome...|$|R
30|$|To {{explore the}} origin of these miRNAs in AMV <b>reverse</b> <b>transcriptase,</b> we traced their source back {{to the process of}} AMV <b>reverse</b> <b>transcriptase</b> production. Currently, there are two primary methods used in <b>reverse</b> <b>transcriptase</b> production; one method is to purify AMV <b>reverse</b> <b>transcriptase</b> from avian {{myeloblastosis}} virus (AMV) particles isolating from the host plasma or cultured cells infected with AMV (Houts et al., 1979); another method is to purify the enzyme following recombinant expression in E. coli or other cells (for example, insect cells). Most commercial AMV <b>reverse</b> <b>transcriptases</b> are produced using the first method. The AMV is used to infect chicks or other birds, after 7  days, AMV particles are purified from the host blood plasma. We checked the miRNA profile of chick plasma by RT-qPCR (Fig.  1 E). The miRNA profile for chick plasma was consistent with that of the <b>reverse</b> <b>transcriptase.</b> There were high concentrations of Let- 7 a, miR- 16, miR- 26 a and miR- 191 in chick plasma, and AMV <b>reverse</b> <b>transcriptase</b> also exhibited high expression levels of these miRNAs (Fig.  1 E and 1 F). Our results suggest that the contaminated miRNA in AMV <b>reverse</b> <b>transcriptase</b> might be derived from host plasma. We suspect that the chick miRNAs are not excluded during AMV <b>reverse</b> <b>transcriptase</b> purification because these miRNAs are binding to the AMV <b>reverse</b> <b>transcriptase.</b>|$|R
40|$|We {{have studied}} the effect of protein phosphokinase (EC 2. 7. 1. 37; ATP:protein phosphotransferase) and phosphoprotein {{phosphatase}} (EC 3. 1. 3. 16; phosphoprotein phosphohydrolase) on <b>reverse</b> <b>transcriptase</b> (RNA-dependent DNA nucleotidyltransferase) activity of Rous sarcoma virus. Protein kinase from Rous sarcoma virus-transformed chick embryo fibroblasts was purified by DEAE-cellulose chromatography, Sephadex gel filtration, and isoelectric focusing. Purified <b>reverse</b> <b>transcriptase</b> from Rouse sarcoma virus was preincubated with protein kinase and ATP under conditions allowing incorporation of phosphate into substrate protein. After the preincubation, <b>reverse</b> <b>transcriptase</b> activity was assayed {{in the presence of}} poly(rA). oligo(dT) as template. A 2 - to 5 -fold increase of <b>reverse</b> <b>transcriptase</b> activity was found after the preincubation of <b>reverse</b> <b>transcriptase</b> with protein kinase and ATP. Incubation of <b>reverse</b> <b>transcriptase</b> with heat-treated, inactive protein kinase and ATP had no effect on transcriptase activity. When the transcriptase preparation was incubated with protein kinase and [gamma- 32 P]ATP and subsequently purified by chromatography on phosphocellulose and Sephadex gel filtration, significant amounts of 32 P-labeled proteins were found in the fractions exhibiting <b>reverse</b> <b>transcriptase</b> activity, suggesting 32 P incorporation into transcriptase or transcriptase-associated proteins. A 20 - 60 % decrease of <b>reverse</b> <b>transcriptase</b> activity was observed after incubation of <b>reverse</b> <b>transcriptase</b> with phosphatase. The results suggest that phosphorylative modification of <b>reverse</b> <b>transcriptase</b> may be critical in the regulation of reverse transcriptase-catalyzed DNA synthesis...|$|R
40|$|Monoclonal {{antibodies}} to {{human immunodeficiency virus}} (HIV) - 2 <b>reverse</b> <b>transcriptase</b> have been raised with {{the ultimate goal of}} generating Fab fragments for future co-crystallization studies. A number of mouse monoclonal {{antibodies to}} recombinant HIV- 2 <b>reverse</b> <b>transcriptase</b> have been obtained and characterized in terms of the possible epitopes they recognise together with cross-reactivity with a related <b>reverse</b> <b>transcriptase.</b> The antibodies were shown to fall into three groups that recognize different regions of the <b>reverse</b> <b>transcriptase</b> enzyme. One antibody, which recognizes part of the RNase H domain, demonstrated cross-reactivity between the HIV- 1 and HIV- 2 <b>reverse</b> <b>transcriptase...</b>|$|R
2500|$|Non-Nucleoside <b>reverse</b> <b>transcriptase</b> inhibitors (NNRTI) inhibit <b>reverse</b> <b>transcriptase</b> by binding to an {{allosteric}} {{site of the}} enzyme; NNRTIs act as non-competitive inhibitors of <b>reverse</b> <b>transcriptase.</b> [...] NNRTIs affect the handling of substrate (nucleotides) by <b>reverse</b> <b>transcriptase</b> by binding near the active site. [...] NNRTIs can be further classified into 1st generation and 2nd generation NNRTIs. 1st generation NNRTIs include nevirapine and efavirenz. 2nd generation NNRTIs are etravirine and rilpivirine. HIV-2 is naturally resistant to NNRTIs.|$|R
5000|$|Non-nucleoside <b>reverse</b> <b>transcriptase</b> inhibitors (NNRTI) inhibit <b>reverse</b> <b>transcriptase</b> by binding to an {{allosteric}} site on it. Cessation of a non-nucleoside <b>reverse</b> <b>transcriptase</b> inhibitor regimen poses a significant danger of selection for a drug-resistant form of HIV-1. A K103N mutation in HIV-1 causes the hydrophobic pocket {{in which the}} NNRTI binds to inhibit enzyme activity in <b>reverse</b> <b>transcriptase</b> to close {{by means of a}} hydrogen bond. Without access to the {{allosteric site}}, the NNRTI will not be effective.|$|R
30|$|RNase {{is usually}} {{strictly}} limited during <b>reverse</b> <b>transcriptase</b> production to avoid RNase contamination; otherwise the contaminated RNase will degrade the RNA template in following reverse transcription. Therefore, small RNAs might be co-purified during <b>reverse</b> <b>transcriptase</b> production. According to our results, both AMV and M-MLV <b>reverse</b> <b>transcriptases</b> contain small RNA fragments coming from their host, respectively. During previous studies, {{we were surprised}} to find adding synthetic miRNA molecule into reverse transcription system could slightly change the CT value (data not shown), which provided a possibility that small RNA in <b>reverse</b> <b>transcriptase</b> might be a functional co-factor rather than contamination. Although our preliminary studies revealed that partially depleting part of miRNAs in AMV by mild physical methods did not interrupt the function of AMV, we could not exclude the possibility that miRNAs in AMV or small RNAs in M-MLV is a potential co-factor for <b>reverse</b> <b>transcriptase,</b> because filtration could not eliminate all small RNAs in <b>reverse</b> <b>transcriptase.</b> We propose that the small RNAs existing in <b>reverse</b> <b>transcriptase</b> might be functional. Based on our discovery and hypothesis, further studies {{should focus on the}} analysis of crystal structure of <b>reverse</b> <b>transcriptase</b> and explore the possible binding site for small RNA.|$|R
40|$|Human {{immunodeficiency}} virus (HIV) <b>reverse</b> <b>transcriptase</b> substitutes for temperature-sensitive DNA polymerase I (Pol Its) in Escherichia coli, providing a screen for anti-HIV <b>reverse</b> <b>transcriptase</b> nucleoside analogs in bacteria. Since phosphorylation of nucleosides in E. coli {{is limited to}} thymidine and its derivatives, we coexpressed herpes simplex virus thymidine kinase, an enzyme that phosphorylates {{a wide variety of}} nucleoside analogs, together with HIV <b>reverse</b> <b>transcriptase.</b> Coexpression of herpes simplex virus thymidine kinase and HIV <b>reverse</b> <b>transcriptase</b> rendered Pol Its cells sensitive to dideoxycytidine. Studies with different nucleoside analogs indicate that this bacterial screening system is able to select and identify nucleoside analogs that specifically target HIV <b>reverse</b> <b>transcriptase...</b>|$|R
40|$|AbstractReverse {{transcriptase}} {{of human}} immunodeficiency virus type 1 is a vitalenzyme in the HIV- 1 replication cycle and an attractive target of attempts to arrest a primary viral infection. We designed a vector for eukaryotic expression of the 66 kDa subunit of <b>reverse</b> <b>transcriptase</b> {{under the control of}} the immediate early cytomegalovirus promoter. Efficient transient expression of the 66 kDa subunit of <b>reverse</b> <b>transcriptase</b> was achieved in a variety of cells. Immunostaining of the transfected cells revealed the cytoplasmatic localization of <b>reverse</b> <b>transcriptase.</b> <b>Reverse</b> <b>transcriptase</b> activity was detected in all transfected cell lines. Injection of this plasmid encoding the 66 kDa subunit of <b>reverse</b> <b>transcriptase</b> into mice resulted in strong reverse transcriptase-specific immune responses indicating that the 66 kDa subunit of <b>reverse</b> <b>transcriptase</b> is expressed in vivo. Sera from DNA-immunized mice inhibited reverse transcription in vitro...|$|R
30|$|In {{the present}} study, an aptamer {{directed}} against the <b>reverse</b> <b>transcriptase</b> was analyzed for its potential to attain a temperature-dependent <b>reverse</b> <b>transcriptase</b> (“hot start” RT).|$|R
40|$|AbstractThe <b>reverse</b> <b>transcriptase</b> from AIDS virus, HTLV-III, was {{purified}} and characterized. The purified enzyme has a {{very high}} affinity for template primers (rC) n·(dG) 12 and (rCm) n·(dG) 12 compared to that for (rA) n·(dT) 12. In addition, the HTLV-III <b>reverse</b> <b>transcriptase</b> was able to transcribe (rAm) n·(dT) 12 very efficiently. The ionic requirements are unique {{in the sense that}} HTLV-III <b>reverse</b> <b>transcriptase</b> prefers Mg 2 as divalent ions to transcribe (rC) n·(dG) 12 and (rA) n·(dT) 12. The Mr of the enzyme is 95000 – 98000. Unlike the HTLV-I <b>reverse</b> <b>transcriptase,</b> the HTLV-III enzyme is highly stable and has a much higher activity in the presence of (rC) n·(dG) 12; the Vmax for HTLV-III <b>reverse</b> <b>transcriptase</b> is several-fold higher than that for HTLV-I enzyme. The enzyme activity of the purified <b>reverse</b> <b>transcriptase</b> from HTLV-III was resolved into two peaks on a preparative isoelectric column, one at pH 5. 75 and the other at pH 6. 25. This leads us to conclude that the <b>reverse</b> <b>transcriptase</b> of HTLV-III is biochemically heterogeneous...|$|R
40|$|The {{present study}} {{describes}} the separation and purification of a <b>reverse</b> <b>transcriptase</b> and cellular DNA polymerases {{from the human}} spleen of a patient with myelofibrotic syndrome. The specific requirements with respect to bivalent cations and template-primers for DNA polymerase-alpha, DNA polymerase-beta and DNA polymerase-gamma, {{as well as for}} the <b>reverse</b> <b>transcriptase,</b> are reported. Sedimentation-velocity measurements of the purified enzymes gave values of 150000, 40000, 100000 and 70000 daltons for DNA polymerase-alpha DNA polymerase-beta, DNA polymerase-gamma and the <b>reverse</b> <b>transcriptase</b> respectively. Serological studies have shown that the <b>reverse</b> <b>transcriptase</b> from human spleen is not antigenically related to cellular DNA polymerase-alpha, -beta or -gamma, but is antigenically related to <b>reverse</b> <b>transcriptase</b> from simian sarcoma virus and gibbon-ape leukaemia virus...|$|R
50|$|Elvucitabine {{belongs to}} a class (group) of HIV drugs called {{nucleoside}} <b>reverse</b> <b>transcriptase</b> inhibitors (NRTIs). NRTIs block an HIV enzyme called <b>reverse</b> <b>transcriptase.</b> (An enzyme is a protein that starts or increases {{the speed of a}} chemical reaction). By blocking <b>reverse</b> <b>transcriptase,</b> NRTIs prevent HIV from multiplying and can reduce the amount of HIV in the body.|$|R
40|$|We {{evaluated}} the new low-cost ExaVir Load (version 3) <b>reverse</b> <b>transcriptase</b> viral load assay against the Roche Cobas Amplicor assay. Results for samples tested using the <b>reverse</b> <b>transcriptase</b> assay correlated well with those obtained with the Roche assay (r = 0. 85; n = 202). The version 3 <b>reverse</b> <b>transcriptase</b> assay shows improved sensitivity {{compared to the}} previous version...|$|R
40|$|The {{organization}} of the murine leukemia virus (MuLV) pol gene was investigated by expressing molecular clones containing AKR MuLV <b>reverse</b> <b>transcriptase</b> or endonuclease or both gene segments in Escherichia coli and generating specific antisera against the expressed bacterial proteins. Reaction of these antisera with detergent-disrupted virus precipitated an 80 -kilodalton (kDa) protein, the MuLV <b>reverse</b> <b>transcriptase,</b> and a 46 -kDa protein which we believe is the viral endonuclease. A third (50 -kDa) protein, related to <b>reverse</b> <b>transcriptase,</b> was also precipitated. Bacterial extracts of clones expressing <b>reverse</b> <b>transcriptase</b> and endonuclease sequences competed with the viral 80 - and 46 -kDa proteins, respectively. These results demonstrate that the antisera are specific for viral <b>reverse</b> <b>transcriptase</b> and endonuclease. Immunoprecipitation of AKR MuLV with antisera prepared against a bacterial protein containing only endonuclease sequences led to the observation that <b>reverse</b> <b>transcriptase</b> and endonuclease can be associated as a complex involving a disulfide bond(s) ...|$|R
25|$|An {{improved}} {{knowledge of}} the action of <b>reverse</b> <b>transcriptase</b> has led to better nucleoside analogues to treat HIV infections. One of these drugs, lamivudine, has been approved to treat hepatitis B, which uses <b>reverse</b> <b>transcriptase</b> {{as part of its}} replication process. Researchers have gone further and developed inhibitors that do not look like nucleosides, but can still block <b>reverse</b> <b>transcriptase.</b>|$|R
40|$|The {{fidelity}} of DNA synthesis by <b>reverse</b> <b>transcriptases</b> {{from human}} immunodeficiency virus and other retroviruses was compared by measuring the rates of misincorporation of dCMP {{in the place of}} TMP in cell-free DNA synthesis with polyadenylic acid as the template. The fidelity of {{human immunodeficiency virus}} <b>reverse</b> <b>transcriptase</b> was found to be about one-third of that of the <b>reverse</b> <b>transcriptases</b> of other retroviruses...|$|R
50|$|In contrast, NNRTIs have a {{completely}} different mode of action. NNRTIs block <b>reverse</b> <b>transcriptase</b> by binding directly to the enzyme. NNRTIs are not incorporated into the viral DNA like NRTIs, but instead inhibit the movement of protein domains of <b>reverse</b> <b>transcriptase</b> that are needed {{to carry out the}} process of DNA synthesis. NNRTIs are therefore classified as non-competitive inhibitors of <b>reverse</b> <b>transcriptase.</b>|$|R
50|$|An {{improved}} {{knowledge of}} the action of <b>reverse</b> <b>transcriptase</b> has led to better nucleoside analogues to treat HIV infections. One of these drugs, lamivudine, has been approved to treat hepatitis B, which uses <b>reverse</b> <b>transcriptase</b> {{as part of its}} replication process. Researchers have gone further and developed inhibitors that do not look like nucleosides, but can still block <b>reverse</b> <b>transcriptase.</b>|$|R
50|$|The {{discovery}} of <b>reverse</b> <b>transcriptase</b> {{is one of}} the most important of the modern era of medicine, as <b>reverse</b> <b>transcriptase</b> is the central enzyme in several widespread viral diseases such as AIDS and Hepatitis B. <b>Reverse</b> <b>transcriptase</b> is also an important component of several important techniques in molecular biology, such as the reverse transcription polymerase chain reaction, and diagnostic medicine.|$|R
40|$|The {{ability of}} <b>reverse</b> <b>transcriptase</b> to bind to [3 H]tryptophanyl-tRNA and to {{function}} as DNA polymerase was compared for five temperature-sensitive mutants of avian sarcoma virus. Both activities of the <b>reverse</b> <b>transcriptase</b> {{were found to be}} heat labile in LA 335 and LA 336 as compared with the wild-type parents. For the other mutant viruses, LA 338, LA 343, and LA 672, grown at the permissive temperature, the <b>reverse</b> <b>transcriptase</b> was nearly as heat stable as for the wild-type parents in terms of tRNA binding and DNA polymerase. LA 338, LA 343, and LA 672 showed characteristic defects in their <b>reverse</b> <b>transcriptase</b> when propagated at the nonpermissive temperature; namely, tryptophanyl-tRNA binding and DNA polymerase activities were coordinately decreased in these virions. The reduced enzymatic activities were not entirely due to an inactive <b>reverse</b> <b>transcriptase</b> present in the virions, however, but rather lower amounts of enzyme protein incorporated into the virions contributed to the effect, according to assays of <b>reverse</b> <b>transcriptase</b> antigen by radioimmune competition...|$|R
2500|$|<b>Reverse</b> <b>transcriptase</b> is {{commonly}} used in research to apply the polymerase chain reaction technique to RNA in a technique called reverse transcription polymerase chain reaction (RT-PCR). [...] The classical PCR technique can be applied only to DNA strands, but, {{with the help of}} <b>reverse</b> <b>transcriptase,</b> RNA can be transcribed into DNA, thus making PCR analysis of RNA molecules possible. <b>Reverse</b> <b>transcriptase</b> is used also to create cDNA libraries from mRNA. The commercial availability of <b>reverse</b> <b>transcriptase</b> greatly improved knowledge in the area of molecular biology, as, along with other enzymes, it allowed scientists to clone, sequence, and characterise RNA.|$|R
40|$|Retinol {{molecule}} {{was modified}} {{to predict the}} inhibitors of telomerase <b>reverse</b> <b>transcriptase</b> {{for the treatment of}} arsenical cancer through in silico study. Telomerase activity is expressed in the cancerous conditions which can be the target for anticancer activity by inhibiting telomerase <b>reverse</b> <b>transcriptase</b> enzyme. The inhibitors were predicted through molecular docking of modified retinol with telomerase <b>reverse</b> <b>transcriptase.</b> Taking into account of low binding energy and high binding affinity two new compounds, compound number 606 and compound number 609 were predicted as the inhibitors of telomerase <b>reverse</b> <b>transcriptase</b> for the treatment of arsenical cancer. The prediction of these two compounds was further supported by drug-likeness test through Administration, Distribution, Metabolism, Excretion and Toxicity evaluation. The compounds were also compared with some of the known inhibitors of telomerase <b>reverse</b> <b>transcriptase.</b>  </p...|$|R
40|$|Hepatitis B virus (HBV), like retroviruses, {{replicates}} through reverse transcription. However, {{the identity}} and {{mechanism for the}} synthesis of HBV <b>reverse</b> <b>transcriptase</b> remain unknown. The open reading frame (ORF) for HBV putative <b>reverse</b> <b>transcriptase</b> (pol), {{as a consequence of}} overlapping with the whole ORF of envelope proteins (hepatitis B surface antigens), includes a hypervariable region at the N terminus. Thus, compared with retroviruses, it is unlikely that HBV <b>reverse</b> <b>transcriptase</b> is translated from complete pol ORF in the full-length pregenomic RNA. We have now detected in infected human livers a novel doubly spliced RNA in which one splicing event removed the hypervariable region of the pol gene but retained the conserved region homologous to retroviral <b>reverse</b> <b>transcriptase.</b> The other splicing event deleted the central region of hepatitis B core antigen and thus brought the protease domain which is important for maturation of <b>reverse</b> <b>transcriptase</b> close to that of pol. For this sequence organization, the spliced RNA as the possible template for the synthesis of HBV <b>reverse</b> <b>transcriptase</b> is discussed...|$|R
30|$|The ART regimen was {{constituted}} of {{combination of}} Nucleoside analogue <b>reverse</b> <b>transcriptase</b> inhibitors (NRTIs) Zidovudine, Lamivudine and Stavuidine (three types) and nonnucleoside analogue <b>reverse</b> <b>transcriptase</b> inhibitors (NNRTIs) Nevirapine and Efavarinz (two types) as ART medications.|$|R
40|$|Retroviral <b>reverse</b> <b>transcriptase</b> {{possesses}} DNA polymerase and ribonuclease H (RNase H) activity {{within a}} single polypeptide. Chemical or proteolytic treatment of <b>reverse</b> <b>transcriptase</b> {{has been used in}} the past to produce enzyme that is missing DNA polymerase activity and retains RNase H activity. It has not been possible to obtain <b>reverse</b> <b>transcriptase</b> that lacks RNase H but retains DNA polymerase activity. We have constructed a novel deletion derivative of the cloned Moloney murine leukemia virus (M-MLV) <b>reverse</b> <b>transcriptase</b> gene, expressed the gene in E. coli, and purified the protein to near homogeneity. The purified enzyme has a fully active DNA polymerase, but has no detectable RNase H activity. These results are consistent with, but do not prove, the conclusion that the DNA polymerase and RNase H activities of M-MLV <b>reverse</b> <b>transcriptase</b> reside within separate structural domains...|$|R
40|$|Using {{synthetic}} oligonucleotides {{corresponding to}} the amino acid sequences best conserved among retroviral <b>reverse</b> <b>transcriptases,</b> we developed a rapid method to detect cloned DNA fragments with the genes for <b>reverse</b> <b>transcriptases.</b> By this technique followed by nucleotide sequence determination, nucleotide sequences coding for reverse transcriptase-like enzymes were identified in two Drosophila retrotransposons, gypsy and 412. Our sequence analysis suggested that {{there are at least}} two major groups of retrotransposons in Drosophila with respect to putative <b>reverse</b> <b>transcriptases</b> and both gypsy and 412 belong to a category of retrotransposons which have putative <b>reverse</b> <b>transcriptases</b> very similar in amino acid sequence to the counterpart of Moloney murine leukaemia virus, a typical mammalian retrovirus...|$|R
50|$|Viral {{proteins}} {{involved in}} {{early stages of}} replication include <b>reverse</b> <b>transcriptase</b> and integrase. <b>Reverse</b> <b>transcriptase</b> is the virally encoded RNA-dependent DNA polymerase. The enzyme uses the viral RNA genome as a template for the synthesis of a complementary DNA copy. <b>Reverse</b> <b>transcriptase</b> also has RNaseH activity for destruction of the RNA-template. Integrase binds both the viral cDNA generated by <b>reverse</b> <b>transcriptase</b> and the host DNA. Integrase processes the LTR before inserting the viral genome into the host DNA. Tat acts as a trans-activator during transcription to enhance initiation and elongation. The Rev responsive element acts post-transcriptionally, regulating mRNA splicing and transport to the cytoplasm.|$|R
40|$|INTRODUCTION: Current Portuguese HIV {{treatment}} guidelines recommend initiating antiretroviral {{therapy with}} a regimen {{composed of two}} Nucleoside <b>Reverse</b> <b>Transcriptase</b> Inhibitors plus one Non-nucleoside <b>Reverse</b> <b>Transcriptase</b> Inhibitor (2 NRTI+NNRTI) or two Nucleoside <b>Reverse</b> <b>Transcriptase</b> Inhibitors plus one boosted protease inhibitor (2 NRTI+PI/r). Given the lower daily cost of NNRTI as the third agent {{when compared to the}} average daily costs of PI/r, it is relevant to estimate the long term impact of each treatment option in the Portuguese context. METHODS: We developed a microsimulation discrete events model for cost-effectiveness analysis of HIV treatment, simulating individual paths from ART initiation to death. Four driving forces determine the course of events: CD 4 + cell count, viral load, resistance and adherence. Distributions of time to event are conditional to individuals' characteristics and past history. Time to event was modeled using parametric survival analysis using Stata 11 ®. Disease progression was structured according to therapy lines and the model was parameterized with cohort Portuguese observational data. All resources were valued at 2009 prices. The National Health Service's perspective was assumed considering a lifetime horizon and a 5 % annual discount rate. RESULTS: In this analysis, initiating therapy with two Nucleoside <b>Reverse</b> <b>Transcriptase</b> Inhibitors plus one Non-nucleoside <b>Reverse</b> <b>Transcriptase</b> Inhibitor reduces the average number of switches by 17 %, saves 19. 573 € per individual and increases life expectancy by 1. 7 months showing to be a dominant strategy in 57 % of the simulations when compared to two Nucleoside <b>Reverse</b> <b>Transcriptase</b> Inhibitors plus one boosted protease inhibitor. CONCLUSION: This study suggests that, when clinically valid, initiating therapy with two Nucleoside <b>Reverse</b> <b>Transcriptase</b> Inhibitors plus one Non-nucleoside <b>Reverse</b> <b>Transcriptase</b> Inhibitor is a cost-saving strategy and equally effective when compared to two Nucleoside <b>Reverse</b> <b>Transcriptase</b> Inhibitors plus one boosted protease inhibitor as the first regimen...|$|R
40|$|Diversity-generating retro{{elements}} (DGRs) are a {{class of}} genetic elements that create massive diversity in a target protein. DGRs are capable of creating at least 1020 unique amino acid sequences. The only other systems known to create such diversity in proteins {{are found in the}} adaptive immune systems of vertebrates. DGRs were initially discovered in the temperate bacteriophage BPP- 1. This DGR was shown to be beneficial to the phage because it enables the phage to adapt to changes in its host. DGRs operate in a reverse transcriptase-mediated and template- dependent process. The DGR <b>reverse</b> <b>transcriptase</b> has the unique ability to create adenine-specific infidelity. DGR <b>reverse</b> <b>transcriptases</b> belong to a distinct clade of <b>reverse</b> <b>transcriptases,</b> one that little is known about. This thesis focuses on the characterization of such <b>reverse</b> <b>transcriptases</b> from two thermophilic bacteria. Thermus aquaticus was previously identified as encoding a DGR. In this thesis, I show that the T. aquaticus <b>reverse</b> <b>transcriptase,</b> when expressed recombinantly in Escherichia coli, likely forms soluble aggregates and is not amenable to purification. Additionally, I identify Caloramator australicus as a thermophilic bacterium with a DGR. I developed a means to express and purify a truncated version of the C. australicus <b>reverse</b> <b>transcriptase,</b> termed CalRT- 33. I show that CalRT- 33 is thermostable but does not form a stable complex with the accessory variable determinant, which is distinct from the case for the BPP- 1 <b>reverse</b> <b>transcriptase</b> and its accessory variability determinant. Lastly, I identify future directions for the study of DGR <b>reverse</b> <b>transcriptases</b> from thermophilic organism...|$|R
40|$|Several newly {{synthesized}} {{polyadenylic acid}} [(A) n] analogues, including poly(2 -methyladenylic acid) [(m 2 A) n], poly(2 -ethyladenylic acid) [(e 2 A) n], poly(2 -isopropyladenylic acid) [(i-pro 2 A) n], poly(2 -methylthioadenylic acid) [(ms 2 A) n], poly(2 -ethylthioadenylic acid) [(e 2 A) n], poly(2 '-fluoro- 2 '-deoxyadenylic acid) [(dAfl) n] and poly(2 '-azido- 2 '-deoxyadenylic acid) [(dAz) n] {{have been evaluated}} for their effects on the RNA-directed DNA polymerase (<b>reverse</b> <b>transcriptase)</b> activity of Moloney murine leukemia virus; (m 2 A) n and (e 2 A) n did not markedly affect <b>reverse</b> <b>transcriptase</b> activity, (dAfl) n served as an efficient template for the <b>reverse</b> <b>transcriptase</b> reaction, and (i-pro 2 A) n, (ms 2 A) n, (es 2 A) n and (dAz) n strongly inhibited <b>reverse</b> <b>transcriptase</b> activity. (dAfl) n also served as an efficient template (Km : 0. 025 micron) for the <b>reverse</b> <b>transcriptase</b> of avian myeloblastosis virus. status: publishe...|$|R
40|$|Introduction: Current Portuguese HIV {{treatment}} guidelines recommend initiating antiretroviral {{therapy with}} a regimen {{composed of two}} Nucleoside <b>Reverse</b> <b>Transcriptase</b> Inhibitors plus one Non-nucleoside <b>Reverse</b> <b>Transcriptase</b> Inhibitor (2 NRTI+NNRTI) or two Nucleoside <b>Reverse</b> <b>Transcriptase</b> Inhibitors plus one boosted protease inhibitor (2 NRTI+PI/r). Given the lower daily cost of NNRTI as the third agent {{when compared to the}} average daily costs of PI/r, it is relevant to estimate the long term impact of each treatment option in the Portuguese context...|$|R
